share_log

8-K: Poll Results of 2024 Stockholders Meeting

8-K: Poll Results of 2024 Stockholders Meeting

8-K：2024年股東大會會議決議公告
美股SEC公告 ·  2024/10/01 04:53

Moomoo AI 已提取核心訊息

Applied DNA Sciences held its 2024 annual meeting on September 30, where shareholders approved all four key proposals. The meeting resulted in the successful election of six directors to serve until the 2025 annual meeting, and the ratification of Marcum LLP as the company's independent registered public accounting firm.Significantly, shareholders granted the board discretionary authority for 12 months to implement a reverse stock split at a ratio ranging from 1:5 to 1:50, with the specific ratio to be determined by the board. Additionally, stockholders approved the exercisability of common stock purchase warrants issued in May 2024, along with the issuance of underlying common stock, in accordance with Nasdaq Listing Rule 5635(d).
Applied DNA Sciences held its 2024 annual meeting on September 30, where shareholders approved all four key proposals. The meeting resulted in the successful election of six directors to serve until the 2025 annual meeting, and the ratification of Marcum LLP as the company's independent registered public accounting firm.Significantly, shareholders granted the board discretionary authority for 12 months to implement a reverse stock split at a ratio ranging from 1:5 to 1:50, with the specific ratio to be determined by the board. Additionally, stockholders approved the exercisability of common stock purchase warrants issued in May 2024, along with the issuance of underlying common stock, in accordance with Nasdaq Listing Rule 5635(d).
Applied DNA Sciences於2024年9月30日召開了年度股東大會，股東們批准了所有四項主要提案。會議成功選舉了六名董事，任期至2025年年度股東大會，並確認Marcum LLP爲公司的獨立註冊公共會計師。重要的是，股東授予董事會12個月的自由裁量權，以實施1:5至1:50的反向股票拆分，具體比例由董事會決定。此外，股東還批准了在2024年5月發行的普通股購股權的可行使性，以及根據納斯達克上市規則5635(d)發行基礎普通股。
Applied DNA Sciences於2024年9月30日召開了年度股東大會，股東們批准了所有四項主要提案。會議成功選舉了六名董事，任期至2025年年度股東大會，並確認Marcum LLP爲公司的獨立註冊公共會計師。重要的是，股東授予董事會12個月的自由裁量權，以實施1:5至1:50的反向股票拆分，具體比例由董事會決定。此外，股東還批准了在2024年5月發行的普通股購股權的可行使性，以及根據納斯達克上市規則5635(d)發行基礎普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Biodesix
    BDSX
    -- 1.030
    bioAffinity Technologies
    BIAF
    -- 0.710
    ProPhase Labs
    PRPH
    -- 0.540
    Grail
    GRAL
    -- 28.610
    燃石醫學
    BNR
    -- 7.317
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啓，全球股市新風口在哪裏？
    ▪️加密貨幣政策能否利好crypto? ▪️關稅政策能否利好中概等海外資產？ ▪️在特朗普政策下，有哪些投資機會值得關注？ 展开
    離川普上臺只有7天了～
    熱門中概股
    追蹤最熱門的中概股實時資訊。